TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 40 - 75 years old~* History of Stable CAD~* Currently receiving statin as standard of care~Exclusion Criteria:~* Severe angina pectoris symptoms~* High-risk coronary or carotid artery disease that will likely require surgical or percutaneous intervention during the study period~* Hospitalization for heart failure within 12 months prior to screening~* Uncontrolled Hypertension~* Within 6 months prior to screening, a history of ACS or hospitalization for heart failure~* Clinically significant abnormalities in rhythm, conduction or morphology of ECG~* Subjects with transplanted heart, left ventricular assist device, implanted pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy~* Untreated life-threatening ventricular arrhythmias~* History, within 12 months prior to screening, of myocarditis or restrictive pericarditis, or hemodynamically significant valvular hear disease or aortic disease~* Undergone major surgery with in 3 months prior to screening or has planned major surgery during the study period

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MEDI6012 24 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
- MEDI6012 80 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
- MEDI6012 240 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
- MEDI6012 800 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
- MEDI6012 80 mg SC (Type: EXPERIMENTAL): Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
- Placebo Intravenous (IV) (Type: PLACEBO_COMPARATOR): Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
- MEDI6012 600 mg SC (Type: EXPERIMENTAL): Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
- Placebo Subcutaneous (SC) (Type: PLACEBO_COMPARATOR): Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: \>18 year~2. Have undergone RNY Gastric Bypass \>1 year.~3. Have symptoms of hypoglycemia (altered mental status or level of consciousness, with or without seizure, palpitations, tremor, anxiety/arousal, sweating, hunger, paresthesias, behavioral changes, fatigue, confusion), documented hypoglycemia (blood glucose\<70 mg/dl), hypoglycemic unawareness (recurrent hypoglycemia without symptoms).~Exclusion Criteria:~1. Patient with Diabetes Type 1 or Type 2. Information identified during history taking or subject undergoing treatment of active diabetes.~2. Patient on medications or treatment (insulin, metformin, glyburide, diazoxide, octreotide, calcium channel blockers), which can cause hypoglycemia.~3. Patients with disorders, which can cause hypoglycemia, like untreated hypothyroidism, adrenal insufficiency, and growth hormone deficiency.~4. Complications of RNY i.e. Ulcers and hernia.~5. Current use of glucocorticoids or medications known to affect blood glucose levels.~6. Any patient that is unable to comply with dietary recommendations, technical iPro, glucometer actions or any part of the research protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baseline Phase (Control) (Type: NO_INTERVENTION): iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours.
- Treatment Phase (Glucomannan) (Type: EXPERIMENTAL): iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female study participants with sickle cell disease~2. Participants have had at least 1 episode of vaso-occlusive crisis (VOC) in the past 12 months.~3. Age 12 to 65 years~4. Hemoglobin (Hb) ≥5.5 and ≤10.5 g/dL during screening~5. For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 3 months prior to signing the ICF.~Exclusion Criteria:~1. More than 10 VOCs within the past 12 months that required a hospital, emergency room or clinic visit~2. Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received a RBC transfusion for any reason within 60 days of signing the ICF~3. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the ICF (i.e., a vaso-occlusive event cannot be within 14 days prior to signing the ICF)~4. Hepatic dysfunction characterized by alanine aminotransferase (ALT) \>4 × upper limit of normal~5. Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit; calculated by the central laboratory) \<30 mL/min/1.73 m\^2 or on chronic dialysis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: ACTIVE_COMPARATOR): voxelotor
- Dose 2 (Type: ACTIVE_COMPARATOR): voxelotor
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prognostic and Predictive Impact of uPA/PAI-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* N0 breast cancer patients tumor size \>/= 1 and \</= 5 cm in diameter undergoing standard loco-regional treatment~Exclusion Criteria:~* M1 status

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: NO_INTERVENTION): Low uPA/PAI-1: Observation
- B2 (Type: NO_INTERVENTION): High uPA/PAI-1: Observation
- B3 (Type: NO_INTERVENTION): High uPA/PAI-1: refused randomization
- B1 (Type: ACTIVE_COMPARATOR): High uPA/PAi-1: CMF chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* 18 years of age or older, male or female~* Receiving a stable opioid regimen~* Documented opioid-induced constipation~* Willingness to stop all laxatives and other bowel regimens. The use of constipation rescue medication will be allowed during the study.~Main Exclusion Criteria:~* Life expectancy less than 6 months~* Active substance abuse~* Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other active medical disorders associated with diarrhea or intermittent loose stools or constipation~* Pregnant or breast-feeding~* Any receipt of an investigational medication within 30 days of screening~* History or presence of specific cardiac, neurologic, endocrine and/or psychiatric conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): Placebo
- B (Type: EXPERIMENTAL): NKTR-118

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naturally or surgically menopausal~* Moderate or severe symptoms of vaginal atrophy~* 5% or fewer superficial cells in maturation index of vaginal smear~* Vaginal pH greater than 5.0~* Self reported Most Bothersome Symptom of vaginal dryness or vaginal pain associated with sexual activity, with a severity of moderate or severe at randomization~Exclusion Criteria:~* Uterine bleeding of unknown origin, uterine polyps or symptomatic and/or large uterine fibroids~* Current vaginal infection requiring medication~* Clinically significant abnormal gynecological findings other than signs of vaginal atrophy (e.g.~uterine or vaginal prolapse of Grade 2 or higher)~* Previous participation in any other ospemifene study

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ospemifene 60 mg/day and K-Y® lubricant (Type: EXPERIMENTAL): Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
- Placebo and K-Y® lubricant (Type: PLACEBO_COMPARATOR): Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug to Drug Interaction Study With ASP1941 and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* Stable disease under metformin monotherapy (between 1500-3000~mg/day) or dual therapy with metformin (1500-3000 mg/day) and a Sulfonylureum Derivative (SUD) for at least 3 months~* Fasting Serum Glucose: 7-11.5 mmol/l (after wash-out)~* Stable Fasting Blood Glucose (FBG) at the end of wash-out~* BMI between 18.5 and 40.0 kg/m2, inclusive~Exclusion Criteria:~* Subjects with type 1 diabetes~* Any diabetes related macro-complications, painful diabetic neuropathy, diabetic macular edema or diabetic proliferative retinopathy~* Clinical significant renal disease (CLcr \<60 ml/min as assessed during a 24h creatinine clearance on Day-2~* Recent evidence (e.g. within the last 6 months) of severe hypoglycemia, for example plasma glucose \<3 mmol/l (\<55 mg/dl) or requiring hospitalization~* Pulse \<40 or \>90; Systolic Blood Pressure \>160 mmHg; Diastolic Blood Pressure \> 100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASP1941 + metformin (Type: EXPERIMENTAL): Oral
- Placebo + metformin (Type: PLACEBO_COMPARATOR): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imaging With a Radio Tracer to Guide VT Ablations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ventricular arrhythmias requiring VT Ablation~* Patients must be 18 years of age or older~* Patient must be able to sign consent form~* Patient must be willing to come back for the 6 month visit for additional study procedures~Exclusion Criteria:~* Patient under 18 years old~* Inability to sign consent~* Pregnant Women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imaging Tracer (Type: EXPERIMENTAL): No arms, the Radio tracer will be used in all subjects imaging tests.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal women (defined as no menstruation for more than 48 weeks prior to screening and no other pathological or physiological causes. If in doubt, a serum follicle-stimulating hormone (FSH) test may be performed at screening)~2. Osteopenia ( -2.5 SD\< T-score \< -1.0 SD in DXA )~Exclusion Criteria:~1. Secondary osteoporosis (Systemic glucocorticoid use, aromatase inhibitor, thyrotoxicosis, hypeparathyroidism, etc)~2. Vitamin D deficiency at baseline (25-OH-vitD \<10ng/mL)~3. Active cancer treatment~4. History of vascular thrombosis~5. Bisphosphonate treatment within the last 12months~6. Contraindication for Raloxifene according to the SPC

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raloxifen plus cholecalciferol (Type: ACTIVE_COMPARATOR): Raloxifene 60mg + Cholecalciferol 800 IU
- Cholecalciferol (Type: ACTIVE_COMPARATOR): Cholecalciferol 800 IU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women (postmenopausal for at least two years)~* Men above 50 years~* Treatment for at least five years with alendronate~* BMD T-score total hip \> -2.5~* BMD T-score lumbar spine (L1-L4) \> -4~Exclusion Criteria:~* Any low-energy fracture within the previous five years during alendronate treatment (not including fingers, toes, or skull)~* Low-energy vertebral fracture at any time~* Low-energy hip fracture at any time~* Ongoing treatment with glucocorticoids~* Metabolic bone disease~* Hormone replacement therapy~* Cancer~* Other conditions affecting bone metabolism

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65 years.~2. Able to provide informed consent.~3. Patients hospitalized with pneumonia proved by chest X-ray or CT scan.~4. Confirmed infection with COVID-2019 using RT-PCR or strongly suspected to be infected with pending confirmation studies.~5. Hyper-inflammation defined as elevation in either C-reactive protein (CRP, ≥ 100 mg/L, normal values \<6 mg/L) or ferritin (≥ 900 ng/mL, normal value \<400 ng/mL), in the presence of increased lactate dehydrogenase (LDH, \>220 U/L).~6. And at least one of the following:~   1. Respiratory frequency ≥30/min.~  2. Blood oxygen saturation ≤93% on room air (RA).~  3. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) \<300 \[18\].~  4. Worsening of lung involvement, defined as an increase in number and/or extension of pulmonary areas of consolidation, need for increased FiO2 to maintain stable O2 saturation, or worsening O2 saturation of \>3% with stable FiO2.~Exclusion Criteria:~1. Evidence of concomitant bacterial infection.~2. Concomitant use of other immunosuppressive biologic drugs.~3. Baseline elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \> 5-fold the upper limit of the normal range.~4. Pregnancy.~5. Treatment with any TNFα inhibitor in the past 30 days.~6. Known hypersensitivity to any TNFα inhibitor, murine proteins, or any component of the formulation.~7. Known or suspected active tuberculosis (TB) or a history of incompletely treated or latent TB.~8. Serious co-morbidity, including:~   1. Myocardial infarction (within last month).~  2. Moderate or severe heart failure (New York Heart Association (NYHA) class III or IV).~  3. Hepatic patients child Pugh class C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Study Arms:
- Group 1 (Type: None): Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.
- Group 2 (Type: None): Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable of giving signed informed consent.~2. Male and female patients ≥18 years of age~3. Body weight of \>40 kg~4. Diagnosis of chronic, stable plaque-type psoriasis. If the patient is diagnosed with psoriasis arthritis, the arthritis should be stable.~5. Moderate-to-severe plaque-type psoriasis as defined by Psoriasis Activity and Severity Index (PASI) ≥12, body surface area (BSA) ≥10%, and Investigator Global Assessment (IGA) ≥3.~6. Candidate for systemic antipsoriatic treatment or phototherapy.~Exclusion Criteria:~1. Therapy-resistant psoriasis~2. Unstable psoriasis or psoriatic arthritis with acute deterioration within 4 weeks of the Screening visit.~3. History of allergy or hypersensitivity to any component of the study treatment.~4. Active infection (eg, bacteria, viral, fungal) requiring treatment with systemic antibiotics within 4 weeks of the Screening visit.~5. Malignancy or history of malignancy except for treated (ie, cured) basal cell skin carcinomas.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orismilast modified release tablets 20 mg BID (Type: EXPERIMENTAL): Oral, twice daily morning and evening for 16 weeks
- Orismilast modified release tablets 30 mg BID (Type: EXPERIMENTAL): Oral, twice daily morning and evening for 16 weeks
- Orismilast modified release tablets 40 mg BID (Type: EXPERIMENTAL): Oral, twice daily morning and evening for 16 weeks
- Placebo tablets BID (Type: PLACEBO_COMPARATOR): Oral, twice daily morning and evening for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria.~* Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative.~* Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis.~* Inadequate control of symptoms with NSAID.~Exclusion Criteria:~* Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process.~* Subjects taking high potency opioid analgesics.~* Previous exposure to secukinumab or other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor.~* Ongoing use of prohibited psoriasis treatments / medications.~* Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα.~* Previous treatment with any cell-depleting therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (AIN457) 150 mg s.c. (Type: EXPERIMENTAL): 1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
- Secukinumab (AIN457) 300 mg s.c. (Type: EXPERIMENTAL): 2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete